Technology ID
TAB-2321

Diagnostic Assays and Methods of Use for Detection of Filarial Infection

E-Numbers
E-281-2010-0
Lead Inventor
Nutman, Thomas (NIAID)
Co-Inventors
Fink, Doran (NIAID)
Kubofcik, Joseph (NIAID)
Burbelo, Peter
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
  • Early-stage
  • Pre-clinical
Lead IC
NIAID
ICs
NIAID
The effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult Wuchereria bancrofti (Wb) antigen in blood, but shows variable efficacy due to the complex life cycle of the parasites and cross reactivity with other organisms. This variability may hinder effective lymphatic filariasis elimination efforts. This new technology improves available detection methods through use of an isolated immunoreactive antigen, Wb123, from infective stage larvae (L3) Wb; which results in specific detection early in the infective cycle with reduced cross reactivity. This technology may see wide application in testing and surveillance of lymphatic filariasis as part of the effort to eliminate the disease worldwide.
Commercial Applications
  • Diagnostics testing
  • Infectious disease monitoring
Competitive Advantages
  • Improved detection of early stage lymphatic filariasis
Licensing Contact:
Mattes, Theodoric
theodoric.mattes@nih.gov